Possible findings of genome-wide sequencing
Group 1 | Genetic findings useful for the original clinical or research question |
Group 2 | Any clinically relevant genetic findings, which may have immediate benefits for the patient related to present diseases or clinical conditions |
Group 2A | Diseases for which possible treatments are available (eg, cardiovascular diseases predisposing to sudden cardiac death) |
Group 2B | Diseases for which no available treatment exists (eg, Charcot–Marie–Tooth disease type 1A) |
Group 3 | Genetic mutations related to high risks for future Mendelian diseases |
Group 3A | Information about risks of preventable or treatable diseases (eg, Lynch syndrome or BRCA1/2) |
Group 3B | Information about risks of non-preventable, non-treatable future diseases (eg, Huntington's disease) |
Group 4 | Information about carrier status of mutations for a X linked or an autosomal recessive disorder impacting reproductive life decisions (eg, Tay-Sachs disease, cystic fibrosis) |
Group 5 | Information of variable risk for future diseases. Genetic traits that may be translated into high predisposition for certain complex diseases (eg, ApoE4 and Alzheimer's disease). Most pharmacogenetic variants (eg, β-blockers and β1-adrenergic receptor) |
Group 6 | Information of unknown significance |
Adapted with permission from Ayuso et al.54